Document is current

Documents that mention this clinical trial

Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
https://doi.org/10.1136/jitc-2022-005082

Strategies for improving the management of immune-related adverse events
https://doi.org/10.1136/jitc-2020-001754

Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
https://doi.org/10.1200/jco.23.01498

Cemiplimab for kidney organ transplant recipients with advanced cutaneous squamous cell carcinoma: CONTRAC-1.
https://doi.org/10.1200/jco.2023.41.16_suppl.9519

Acute Kidney Injury in Critically Ill Patients with Cancer
https://doi.org/10.2215/cjn.15681221

Documents that mention this clinical trial

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434

Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients
https://doi.org/10.1136/jitc-2020-000908

Strategies for improving the management of immune-related adverse events
https://doi.org/10.1136/jitc-2020-001754

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956

Acute Kidney Injury in Critically Ill Patients with Cancer
https://doi.org/10.2215/cjn.15681221

Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers
https://doi.org/10.1200/jco.23.01497

Documents that mention this clinical trial

Strategies for improving the management of immune-related adverse events
https://doi.org/10.1136/jitc-2020-001754

Documents that mention this clinical trial

Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
https://doi.org/10.1136/jitc-2020-002097

Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma
https://doi.org/10.1200/jco.24.00640

Strategies for improving the management of immune-related adverse events
https://doi.org/10.1136/jitc-2020-001754

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
https://doi.org/10.1136/jitc-2020-001235

Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
https://doi.org/10.1136/jitc-2022-005128

Documents that mention this clinical trial

Strategies for improving the management of immune-related adverse events
https://doi.org/10.1136/jitc-2020-001754

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
https://doi.org/10.1136/jitc-2020-001235

Documents that mention this clinical trial

Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
https://doi.org/10.1136/jitc-2019-000356

Strategies for improving the management of immune-related adverse events
https://doi.org/10.1136/jitc-2020-001754

Incidence of immune checkpoint inhibitor–mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score–matched retrospective study
https://doi.org/10.1136/jitc-2021-002567

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956

Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study
https://doi.org/10.1136/jitc-2020-000538

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658